Drug Profile
Research programme: cardiovascular disease therapeutics - Incyte/University of Maastricht
Latest Information Update: 19 Sep 2006
Price :
$50
*
At a glance
- Originator Cardiovascular Research Institute Maastricht; Incyte Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 30 Apr 2003 Incyte Genomics is now called Incyte Corporation
- 15 Jan 2003 This programme is still in active development